APAC Infectious Disease Diagnosis Treatment Companies

Top Industry Leaders in the APAC Infectious Disease Diagnosis Treatment Market

Infectious Disease Diagnosis & Treatment Companies

Oct 2023:Ahead of government price talks for its best-selling cancer treatment Imbruvica, AbbVie announced on Friday a $2.1 billion charge associated with anticipated revenue declines following the implementation of the new price for Medicare patients in the United States. With a declared government objective of saving $25 billion annually on prescription costs by 2031, the Illinois-based drugmaker's leukemia medicine was chosen in August as one of the 10 drugs subjected to the first-ever price discussions by U.S. Medicare insurance plans. While the first ten medicine prices are still up for negotiation and will not be implemented until 2026, AbbVie claimed to have projected "a substantial reduction in the estimated future financial flows" from the first ten drug prices since it had utilized an undisclosed placeholder price. The prescribed medications are some of the most expensive for the Medicare program, which covers Americans 65 and older. Imbruvica's third-quarter sales of $908 million were above Wall Street's projections of $863 million.

Oct 2023: Pfizer reported its first quarterly loss before 2019 and recommended investors concentrate on growth in non-COVID goods, including the novel RSV vaccine Abrysvo. A decline hit the drugmaker in demand for COVID-19 vaccines and therapies. The business announced last month that it would take a one-time charge of $5.6 billion to cover the returns of thousands of doses of its antiviral medication Paxlovid by the US government and the inventory of COVID vaccination Comirnaty.

List of APAC Infectious Disease Diagnosis & Treatment Companies in the market